In addition, the anti-tumor function of the ROR1-CAR T cells can be enhanced with SD-208, a highly selective, competitive, and orally bioavailable TGF-β-receptor I kinase inhibitor in a microphysiologic 3D TNBC model (96). The gene discussed is ROR1; the disease is neoplasm.